Arbutus Biopharma Corporation ABUS Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's additional paid-in capital?
- Arbutus Biopharma Corporation (ABUS) reported additional paid-in capital of $74.26M in Q1 2026.
- How has Arbutus Biopharma Corporation's additional paid-in capital changed year-over-year?
- Arbutus Biopharma Corporation's additional paid-in capital decreased by 9.5% year-over-year, from $82.09M to $74.26M.
- What is the long-term trend for Arbutus Biopharma Corporation's additional paid-in capital?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's additional paid-in capital has grown at a 6.5% compound annual growth rate (CAGR), from $60.75M to $83.32M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.